Entos builds out team with Chen as CMO, Ding as CBO
Plus Henderson becomes CEO of Wren, and updates from Bolt, argenx and more
Entos Pharmaceuticals Inc. hired Steve Chen as CMO and Jason Ding as CBO. Chen was CMO at Cellics Therapeutics Inc. and VP of medical development at La Jolla Pharmaceutical Co. (NASDAQ:LJPC). Ding was partner and senior managing director and a national life sciences and healthcare transactions leader at Deloitte LLP. The additions come on the heels of a deal in January with Eli Lilly and Co. (NYSE:LLY) to use Entos’ Fusogenix, a proteo-lipid vehicle nucleic acid delivery platform, for neurological indications.
Cambridge, U.K., and Boston neurodegenerative disease company Wren Therapeutics Ltd. hired Bart Henderson as CEO. A founder of multiple biotechs including Torque Therapeutics Inc., Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) and Fuse Biotherapeutics Inc., Henderson has been an operating partner at Flagship Pioneering and entrepreneur-in-residence at MPM Capital. He also is a veteran of Amgen Inc. (NASDAQ:AMGN), Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD), Merck & Co. Inc. (NYSE:MRK) and Vertex Pharmaceuticals Inc. (NASDAQ:VRTX)...